الفهرس 
Chronic lymphocytic leukemiaOnly 14 pages are availabe for public view
 |  | from | 96 |  |  |
| | | from | 96 | | |
Abstract
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with a highly variable clinical course. Some patients have a life expectancy which resembles that of the age-matched general population, while others progress and need treatment within a few months of diagnosis. Several clinical and biological variables, some of which validated in prospective studies, have been reported to predict the outcome of CLL patients when assessed at presentation of the leukemia. Among them, the old-fashioned but still widely used clinical staging systems initially proposed by Rai and/or Binet, or the more demanding mutational status of the variable region of the heavy-chain locus of the immunoglobulin genes (IGHV) and fluorescent in situ hybridization are the hallmarks for discriminating patients with an aggressive or indolent clinical course. Although the latter methods have been standardized, tests are still expensive and cannot be provided by all laboratories. For this reason, the search for new cytofluorimetric markers is still of great interest, especially after CD38 and ZAP-70 have been shown to have major limitations, the former because of its low prognostic power and the latter because of well-recognized technical problems. Recently, CD38 and other markers, such as CD25, CD26 and CD69, have been advocated as being predictive and reliable in identifying patients with peculiar molecular characteristics of disease. Leukocyte-associated immunoglobulin-like receptor-1 (LAIR1), also known as CD305, is a transmembrane glycoprotein that acts as an inhibitory receptor and is expressed by most immune cells. LAIR1 expression varies during B-cell differentiation and has recently been demonstrated in patients with CLL. The aim of this study was to evaluate the expression of CD305 in chronic lymphocytic leukemia. The present study was conducted on 40 consecutive patients presented to Oncology department, Menoufia University in the period between 9/2014 to 7/2016 and and 14 age and sex matched apparently healthy controls All the enrolled individuals were subjected to the following:
Full history taking and clinical examination.
Assessment of “B2 microglobulin” and “LDH”
Routine laboratory investigations.
Measure the expression of CD305and CD38 on mononuclear cells in CLL patients byflowcytometry.
By analyzing and processing the data obtained from the history, clinical examination and lab work the study declared that:
This study report that a significantly lower proportion of CD305 positive patients who initiated cytotoxic treatment during follow-up compared to CD305 negative patients, while longer follow-up is needed to establish its ability to predict survival.
There is association between CD305 low expression on the surface of B cells and aggressive clinical presentation of the disease
Surface expression of CD38 is an independent adverse prognostic markers in patients with CLL at different stages. Therefore, evaluation of CD38 expression is suggested as a part of routine future panel for prognostic stratification of CLL patients at diagnosis.